Ozanimod - CAS 1306760-87-1
Catalog number: B0084-470834
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Sphingosine 1 Phosphate Receptor
Ozanimod, also known as RPC1063, is a selective oral S1P Receptor 1 modulator.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-470834 50 mg $198 In stock
Bulk Inquiry
Solid Powder
RPC1063; RPC-1063; RPC 1063; Ozanimod; 5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile
DMSO: 81mg/mL(200.26mM); Ethanol: 10mg/mL(24.72mM); Water: <1mg/mL(<1mM)
3 years -20℃ powder; 6 months -80℃ in solvent
Shelf Life:
2 years
Canonical SMILES:
1.The Latest Innovations in the Drug Pipeline for Multiple Sclerosis.
Radick L;Mehr SR Am Health Drug Benefits. 2015 Nov;8(8):448-53.
Several new medications are being investigated in late-phase studies for the treatment of patients with relapsing or progressive multiple sclerosis (MS). These agents represent a variety of mechanisms of action and provide not only lower relapse rates but also improvement in disabilities. The majority of investigational trials involve selective sphingosine-1-phosphate receptor 1 immunomodulators, such as laquinimod, ozanimod, ponesimod, and siponimod, in an effort to build on the success of fingolimod. Ocrelizumab is a CD20-positive B-cell-targeting monoclonal antibody with a promising new mechanism of action. Ofatumumab is also a CD20 inhibitor. Daclizumab, an interleukin-2 inhibitor, has evidence of good efficacy but is associated with unfavorable side effects. Masitinib is a mast-cell inhibitor that also has shown efficacy in Alzheimer's disease and amyotrophic lateral sclerosis. Phase 3 trials for some of these agents will conclude in the next 12 months, and their manufacturers are expected to apply for US Food and Drug Administration approval soon thereafter. This review article summarizes data for newly approved and late-phase investigational agents for the treatment of patients with MS.
2.Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.
Scott FL;Clemons B;Brooks J;Brahmachary E;Powell R;Dedman H;Desale HG;Timony GA;Martinborough E;Rosen H;Roberts E;Boehm MF;Peach RJ Br J Pharmacol. 2016 Jun;173(11):1778-92. doi: 10.1111/bph.13476. Epub 2016 Apr 28.
BACKGROUND AND PURPOSE: ;Sphingosine1-phosphate (S1P) receptors mediate multiple events including lymphocyte trafficking, cardiac function, and endothelial barrier integrity. Stimulation of S1P1 receptors sequesters lymphocyte subsets in peripheral lymphoid organs, preventing their trafficking to inflamed tissue sites, modulating immunity. Targeting S1P receptors for treating autoimmune disease has been established in clinical studies with the non-selective S1P modulator, FTY720 (fingolimod, Gilenya™). The purpose of this study was to assess RPC1063 for its therapeutic utility in autoimmune diseases.;EXPERIMENTAL APPROACH: ;The specificity and potency of RPC1063 (ozanimod) was evaluated for all five S1P receptors, and its effect on cell surface S1P1 receptor expression, was characterized in vitro. The oral pharmacokinetic (PK) parameters and pharmacodynamic effects were established in rodents, and its activity in three models of autoimmune disease (experimental autoimmune encephalitis, 2,4,6-trinitrobenzenesulfonic acid colitis and CD4(+) CD45RB(hi) T cell adoptive transfer colitis) was assessed.;KEY RESULTS: ;RPC1063 was specific for S1P1 and S1P5 receptors, induced S1P1 receptor internalization and induced a reversible reduction in circulating B and CCR7(+) T lymphocytes in vivo.
3.Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges.
Vetter M;Neurath MF Therap Adv Gastroenterol. 2017 Oct;10(10):773-790. doi: 10.1177/1756283X17727388. Epub 2017 Sep 5.
To improve quality of life and prevent long-term risks in patients with inflammatory bowel diseases (IBDs: Crohn's disease, ulcerative colitis), it is essential to suppress inflammatory activity adequately. However, corticosteroids are only suitable for therapy of acute flares and the evidence for positive effects of immunosuppressive substances like azathioprine or 6-mercapropurine is mainly limited to maintenance of remission. In addition, only subgroups of patients benefit from biologicals targeting tumour necrosis factor α or α4β7 integrins. In summary, until now the disease activity is not sufficiently controlled in a relevant fraction of the patients with IBD. Thus, there is an urge for the development of new substances in the therapy of ulcerative colitis and Crohn's disease. Fortunately, new oral and parenteral substances are in the pipeline. This review will focus on oral substances, which have already passed phase II studies successfully at this stage. In this article, we summarize data regarding AJM300, phosphatidylcholine (LT-02), mongersen, ozanimod, filgotinib and tofacitinib. AJM300 and ozanimod were tested in patients with ulcerative colitis and target lymphocyte trafficking through inhibition of the α subunit of integrin, respectively binding to the sphingosine-1-phosphate receptor (subtypes 1 and 5) on lymphocytes.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Sphingosine 1 Phosphate Receptor Products

CAS 1306760-87-1 Ozanimod

(CAS: 1306760-87-1)

Ozanimod, also known as RPC1063, is a selective oral S1P Receptor 1 modulator.

CYM 50358 hydrochloride

The hydrochloride salt form of CYM 50358, which has been found to be an effective S1P4 antagonist.

PF-543 hydrochloride
(CAS: 1706522-79-3)

The hydrochloride salt form of PF-543, a novel SphK1 inhibitor that could exhibit activity in induceing necrosis in human colorectal cancer cells in biological ...

CAS 840523-39-9 CS-0777-P

(CAS: 840523-39-9)

CS-0777 is a selective sphingosine 1-phosphate receptor modulator agonist. It is in clinical trials for the treatment of multiple sclerosis, but no recent devel...

CAS 1345858-76-5 CYM 50308

CYM 50308
(CAS: 1345858-76-5)

CYM 50308 has been found to be an effective and selective S1P4 agonist.

CAS 1355026-60-6 CYM 50260

CYM 50260
(CAS: 1355026-60-6)

CYM 50260 has been found to be a S1P4 agonist.

(CAS: 1236188-38-7)

This active molecular is a selective S1P1 receptor agonist that originated by Bristol-Myers Squibb. BMS-520 shows really good efficacy in animal models of arthr...

CAS 1202073-26-4 AMG 369

AMG 369
(CAS: 1202073-26-4)

This active molecular is a S1P1/S1P5 agonist with limited activity at S1P3. AMG 369 has no activity at S1P2 and S1P4. AMG-369 is shown to reduce blood lymphocyt...

Chemical Structure

CAS 1306760-87-1 Ozanimod

Quick Inquiry

Verification code

Featured Items